In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Pazopanib HCl is a receptor tyrosine kinase inhibitor that targets multiple kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit, and c-Fms, with IC50s 10nM, 30nM, 47nM, 84nM, 74nM, 140nM, and 146nM respectively [1-3]. Pazopanib inhibits both tumor growth and angiogenesis through suppressing these targets. In preclinical studies, it has shown anti-tumor activity against several human tumor xenografts, including renal, prostate, colon, lung, melanoma, head and neck, and breast cancer . It also showed desirable pharmacokinetics and oral bioavailability in animal models .
Pazopanib has been approved for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas by multiple regulatory administrations worldwide, including FDA, EMA, MHRA and TGA. In the clinical trial for soft tissue sarcomas, Pazopanib improved median progression-free survival (PFS) to 4.6 months compared to 1.6 months for patients receiving placebo . In the trial for renal cell carcinoma, Pazopanib increased the median PFS from 4.2 monthe (placebo) to 9.2 months . The most common adverse effect of Pazopanib were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting .
1. Verweij J, Sleijfer S. Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother 2013; 14: 929-935.
2. Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther 2012; 34: 511-520.
3. Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010; 9: 17-18.
4. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9: 115-119.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||≥11.85mg/mL in DMSO|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|
|Description||Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.|
|IC50||10 nM||30 nM||47 nM||84 nM||74 nM|